menu
    • menu
    [{"orgOrder":0,"company":"Novelty Nobility","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novelty Nobility \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Novelty Nobility \/ GC Biopharma"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"ValenzaBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"VB517","moa":"c-KIT","graph1":"Immunology","graph2":"IND Enabling","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novelty Nobility \/ ValenzaBio","highestDevelopmentStatusID":"5","companyTruncated":"Novelty Nobility \/ ValenzaBio"}]

    Find Clinical Drug Pipeline Developments & Deals by Novelty Nobility

    Menu

    Novelty Nobility

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Novelty Nobility

    South Korea arrow
    Peptide Therapy Summit
    Not Confirmed

    Novelty Nobility

    South Korea arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Ophthalmology

    Study Phase : Discovery

    Sponsor : GC Biopharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    GC Biopharma And Novelty Nobility Team Up for Geographic Atrophy R&D

    Details : GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    October 28, 2024

    Lead Product(s) : Undisclosed

    Therapeutic Area : Ophthalmology

    Highest Development Status : Discovery

    Sponsor : GC Biopharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Novelty Nobility

    South Korea arrow
    Peptide Therapy Summit
    Not Confirmed

    Novelty Nobility

    South Korea arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VB517

    Therapeutic Area : Immunology

    Study Phase : IND Enabling

    Sponsor : ValenzaBio

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Mo...

    Details : VB517 is a fully human mAb with low-picomolar affinity for c-KIT and has demonstrated potent suppression of human mast cell activation in preclinical models. ValenzaBio plans to initiate clinical studies of VB517 in 2023.

    Product Name : VB517

    Product Type : Antibody

    Upfront Cash : Undisclosed

    February 15, 2022

    Lead Product(s) : VB517

    Therapeutic Area : Immunology

    Highest Development Status : IND Enabling

    Sponsor : ValenzaBio

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth